Highmark Covering Rosetta Genomics' Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.

Highmark Health is a subsidiary of Highmark and the fourth-largest Blue Cross Blue Shield-affiliated company, providing coverage for 5.3 million people in Pennsylvania, Delaware, and West Virginia. Its members now have access to Rosetta's test for identifying the tumor origin in cancer of unknown or uncertain primary as an in-network service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: Plasmodium knowlesi population structure, 'pre-adaptations' in algal ancestors of land plants, and more.

Replication studies that don't quite reflect the original findings underscore the need to better share data, the Wall Street Journal reports.

About two-thirds of proposals to work with select agents are denied — though most proposals that come in don't meet the definition of a restricted experiment, according to an analysis by the Centers for Disease Control and Prevention.

Researchers examine plant and human DNA found on the Shroud of Turin.